Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FUNGEMAX: Nal-IRI vs Gemcitabine/Nab-Paclitaxel in Metastatic Pancreatic Cancer
NCT03693677Phase 2Completed
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Nov 2018
- Primary completion
- Jan 2025
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of nanoliposomal irinotecan in pancreatic adenocarcinoma (PDAC) (3 arms), sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoint: Progression Free Survival at 6 months. Started Nov 2018; status: completed.
02
Drugs
nanoliposomal irinotecan
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03693677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03693677.